Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Efficacy and Tolerability of Different Interventions in Children and Adolescents with Attention Deficit Hyperactivity Disorder.

Luan R, Mu Z, Yue F, He S.

Front Psychiatry. 2017 Nov 13;8:229. doi: 10.3389/fpsyt.2017.00229. eCollection 2017.

2.

Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.

Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Hollis C, Kovshoff H, McCarthy S, Nagy P, Sonuga-Barke E, Wong IC, Zuddas A, Rosenthal E, Buitelaar JK; ADDUCE consortium.

CNS Drugs. 2017 Mar;31(3):199-215. doi: 10.1007/s40263-017-0410-7. Review.

3.

Changes in behavior as side effects in methylphenidate treatment: review of the literature.

Konrad-Bindl DS, Gresser U, Richartz BM.

Neuropsychiatr Dis Treat. 2016 Oct 12;12:2635-2647. eCollection 2016. Review.

4.

Comparative efficacy of methylphenidate and atomoxetine in the treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review and meta-analysis.

Rezaei G, Hosseini SA, Akbari Sari A, Olyaeemanesh A, Lotfi MH, Yassini M, Bidaki R, Nouri B.

Med J Islam Repub Iran. 2016 Feb 10;30:325. eCollection 2016.

5.

A systematic review of randomized controlled trials of bupropion versus methylphenidate in the treatment of attention-deficit/hyperactivity disorder.

Maneeton N, Maneeton B, Intaprasert S, Woottiluk P.

Neuropsychiatr Dis Treat. 2014 Aug 1;10:1439-49. doi: 10.2147/NDT.S62714. eCollection 2014.

6.

Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments.

Jordan CJ, Harvey RC, Baskin BB, Dwoskin LP, Kantak KM.

Drug Alcohol Depend. 2014 Jul 1;140:25-32. doi: 10.1016/j.drugalcdep.2014.04.020. Epub 2014 Apr 28.

7.

Atomoxetine affects transcription/translation of the NMDA receptor and the norepinephrine transporter in the rat brain--an in vivo study.

Udvardi PT, Föhr KJ, Henes C, Liebau S, Dreyhaupt J, Boeckers TM, Ludolph AG.

Drug Des Devel Ther. 2013 Dec 4;7:1433-46. doi: 10.2147/DDDT.S50448. eCollection 2013.

8.

Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.

Kornfield R, Watson S, Higashi AS, Conti RM, Dusetzina SB, Garfield CF, Dorsey ER, Huskamp HA, Alexander GC.

Psychiatr Serv. 2013 Apr 1;64(4):339-46. doi: 10.1176/appi.ps.201200147.

9.

A liquid chromatography/tandem mass spectrometry assay for the analysis of atomoxetine in human plasma and in vitro cellular samples.

Appel DI, Brinda B, Markowitz JS, Newcorn JH, Zhu HJ.

Biomed Chromatogr. 2012 Nov;26(11):1364-70. doi: 10.1002/bmc.2706. Epub 2012 Jan 25.

11.

Patient characteristics, comorbidities, and medication use for children with ADHD with and without a co-occurring reading disorder: A retrospective cohort study.

Classi PM, Le TK, Ward S, Johnston J.

Child Adolesc Psychiatry Ment Health. 2011 Dec 6;5:38. doi: 10.1186/1753-2000-5-38.

12.
13.

A randomized, open-label assessment of response to various doses of atomoxetine in korean pediatric outpatients with attention-deficit/hyperactivity disorder.

Cho S, Lee SI, Yoo H, Song DH, Ahn DH, Shin DW, Yum SY, Walton R, Mendez L.

Psychiatry Investig. 2011 Jun;8(2):141-8. doi: 10.4306/pi.2011.8.2.141. Epub 2011 Jan 19.

14.

Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists.

Fernando AB, Economidou D, Theobald DE, Zou MF, Newman AH, Spoelder M, Caprioli D, Moreno M, Hipólito L, Aspinall AT, Robbins TW, Dalley JW.

Psychopharmacology (Berl). 2012 Jan;219(2):341-52. doi: 10.1007/s00213-011-2408-z. Epub 2011 Jul 15.

15.

Non-stimulant treatment for attention deficit hyperactivity disorder.

Budur K, Mathews M, Adetunji B, Mathews M, Mahmud J.

Psychiatry (Edgmont). 2005 Jul;2(7):44-8. No abstract available.

16.

Adult ADHD: Diagnosis, Differential Diagnosis, and Medication Management.

Gentile JP, Atiq R, Gillig PM.

Psychiatry (Edgmont). 2006 Aug;3(8):25-30. No abstract available.

17.

A review of long-acting medications for ADHD in Canada.

Hosenbocus S, Chahal R.

J Can Acad Child Adolesc Psychiatry. 2009 Nov;18(4):331-9.

18.

Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants.

Buitelaar J, Medori R.

Eur Child Adolesc Psychiatry. 2010 Apr;19(4):325-40. doi: 10.1007/s00787-009-0056-1. Epub 2009 Oct 13. Review.

19.

Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review.

Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D.

Neuropsychiatr Dis Treat. 2009;5:215-26. Epub 2009 Apr 8.

20.

Atomoxetine: a novel treatment for child and adult ADHD.

Ledbetter M.

Neuropsychiatr Dis Treat. 2006 Dec;2(4):455-66.

Supplemental Content

Support Center